Dry AMD treatment facilitated by swept-source OCT imaging

August 23, 2021

Article

Option detects treatment-naive nonexudative macular neovascularization in eyes with dry age-related macular degeneration.

Dry AMD treatment facilitated by swept-source OCT imaging

Reviewed by Philip J. Rosenfeld, MD, PhD.

Treatment-naive nonexudative macular neovascularization (MNV) is now recognized as a state of age-related macular degeneration (AMD) that can be accurately detected with swept-source optical coherence tomography angiography (SS-OCTA). Although nonexudative MNV is asymptomatic, it is important to identify these lesions because they seem to be a precursor for the development of exudative disease, according to Philip J. Rosenfeld, MD, PhD.

Rosenfeld discussed the detection, natural history, and management of treatment-naive MNV in a presentation at the 2021 Ohio Ophthalmological Society Virtual Annual Meeting.

“A double-layer sign (DLS) or shallow, irregular retinal pigment epithelial elevation (SIRE) on the structural OCT B-scan is a characteristic feature of these lesions,” said Rosenfeld, a professor of ophthalmology at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine in Florida. “Finding these lesions in eyes with dry AMD is important because they have a high risk of conversion to exudative AMD. So far, we have not been able to predict which eyes are likely to progress to exudation based on anatomic changes. Therefore, close follow-up and at-home monitoring [are] crucial in these patients to prevent vision loss.”

Rosenfeld highlighted his message about monitoring with a case history involving a patient who presented in January 2020 with large drusen and 20/40 visual acuity (VA) OU. Routine SS-OCT showed structural elevation of the retinal pigment epithelium (RPE) consistent with drusen in the right eye but no evidence of exudation.

Nonexudative MNV was detected with SS-OCTA imaging, where the areas of confluent drusen corresponded to a DLS seen on individual B-scans.Segmentation of RPE-Bruch’s membrane on the SS-OCTA angiographic flow map showed the patient had 3 independent neovascular complexes.

The patient was counseled to return for follow-up in March 2020, but because of the COVID-19 pandemic, she canceled that appointment. A rescheduled visit in April was also canceled. In May, 4 months after her January appointment, she presented to the emergency department because of sudden vision loss in the right eye. Examination showed count-fingers VA and identified a massive submacular hemorrhage along with exudation.

“This situation could have been prevented by home monitoring and even better by home OCT monitoring that could have showed exudation developing long before the hemorrhage occurred,” he said.

Detecting MNV on OCTA

Rosenfeld credited the ability to detect MNV to the work by Ruikang Wang, PhD, of the University of Washington in Seattle, who developed an optical microangiography algorithm that enables flow detection in OCT images. Using specific segmentation strategies, clinicians can identify subclinical MNV lesions using a number of different slab configurations with different boundaries. For the purposes of his study, Rosenfeld used a slab that extended from the outer retina (OR) to the choriocapillaris (CC), which is termed the ORCC slab.

Looking back, Rosenfeld noted that the presence of subclinical MNV had been described in the 1990s in eyes that had undergone indocyanine green angiography (ICGA). The ability to identify these lesions equally as well using noninvasive SS-OCTA imaging was demonstrated by Rosenfeld and colleagues in a study of patients with asymptomatic, intermediate AMD in one eye and exudative NV AMD in the fellow eye.¹

Subsequently, Rosenfeld and colleagues went on to investigate the prevalence and natural history of nonexudative MNV in dry AMD. For this study, they included patients with dry AMD in one eye and a fellow eye with exudative AMD. In the eyes with dry AMD, they found a 14-fold increased risk of developing exudation within 2 years among eyes with nonexudative MNV compared with eyes that did not have subclinical MNV.²

Overall, if the fellow eye had exudative AMD, the prevalence of a nonexudative MNV in an eye with dry AMD was 13%. The prevalence was similar in eyes with either intermediate AMD or geographic atrophy.

Follow-up of eyes with nonexudative MNV showed that the lesions can grow without becoming exudative. Anti-VEGF treatment was administered when symptomatic fluid developed associated with a decrease in vision, and the treatment was effective in resolving the fluid and improving VA, but there were no obvious effects on lesion morphology for type 1 MNV, which comprised 93% of the lesions.

Search for anatomic changes that predict exudation

Studies conducted to find possible biomarkers to predict exudative conversion have so far shown no association with size or growth of the MNV prior to exudation or with changes in volume of pigment epithelial detachments associated with the MNV prior to exudation, choriocapillaris flow deficits, or the surrounding choroidal vasculature.³

“Additional potential predictors we are looking at include flow velocity within the MNV or in the choriocapillaris around the MNV and changes in choroidal blood flow,” Rosenfeld noted.
“However, findings from research using the complement inhibitor pegcetacoplan suggest that immunological triggers are the most likely cause for exudation.”

Rosenfeld explained that in the phase 2 FILLY study investigating pegcetacoplan for the treatment of geographic atrophy, the adverse event analysis showed that new-onset exudation developed in a dose-dependent fashion, occurring in 21% of eyes treated monthly with the investigational agent, in 9% of eyes receiving treatment every other month, and in only 1 eye (1.2%) in the sham-treated control group.⁴

A post hoc review of images obtained at baseline showed the DLS was present in 73% of eyes that developed exudative AMD versus in 32% that did not develop exudation.⁵

“These eyes with the DLS had subclinical neovascularization, but we were not prepared to capture these eyes at baseline,” Rosenfeld explained. “Now, in the phase 3 trials investigating pegcetacoplan, DLS at baseline is being identified, and these eyes are being followed carefully for the development of exudation that will be treated with anti-VEGF therapy.”

However, Rosenfeld added that the take-home message from FILLY “is that the VA outcome was just as good in eyes that developed exudation compared to those that did not because they were treated promptly with and responded very well to anti-VEGF therapy.”

Philip J. Rosenfeld, MD, PhD

E: prosenfeld@med.miami.edu

This article is based on Rosenfeld’s presentation at the 2021 Ohio Ophthalmological Society Virtual Annual Meeting. Rosenfeld receives research support from and is a consultant to Carl Zeiss Meditec and is chairman of the steering committee of the Advanced Retina Imaging Network, which is a global consortium of clinical researchers and the Zeiss Medical Technology business group.

References

1. Roisman L, Zhang Q, Wang RK, et al. Optical coherence tomography angiography of asymptomatic neovascularization in intermediate age-related macular degeneration. Ophthalmology. 2016;123(6):1309-1319. doi:10.1016/j.ophtha.2016.01.044

2. Yang J, Zhang Q, Motulsky EH, et al. Two-year risk of exudation in eyes with nonexudative age-related macular degeneration and subclinical neovascularization detected with swept source optical coherence tomography angiography. Am J Ophthalmol. 2019;208:1-11. doi:10.1016/j.ajo.2019.06.017

3. Shen M, Zhang Q, Yang J, et al. Swept-source oct angiographic characteristics of treatment-naive nonexudative macular neovascularization in amd prior to exudation. Invest Ophthalmol Vis Sci. 2021;62(6):14. doi:10.1167/iovs.62.6.14

4. Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2020;127(2):186-195. doi:10.1016/j.ophtha.2019.07.011

5. Wykoff CC, Rosenfeld PJ, Waheed NK, et al. Characterizing new-onset exudation in the randomized phase 2 FILLY trial of complement inhibitor pegcetacoplan for geographic atrophy. Ophthalmology. Published online March 10, 2021. doi:10.1016/j.ophtha.2021.02.025

Related Content: Imaging | AMD | Ophthalmology